Skip to Content

Generic Ferriprox Availability

Last updated on Sep 8, 2021.

Ferriprox is a brand name of deferiprone, approved by the FDA in the following formulation(s):

FERRIPROX (deferiprone - solution;oral)

  • Manufacturer: CHIESI
    Approval date: September 9, 2015
    Strength(s): 100MG/ML [RLD]
  • Manufacturer: CHIESI
    Approval date: April 20, 2018
    Strength(s): 80MG/ML (discontinued) [RLD]

FERRIPROX (deferiprone - tablet;oral)

  • Manufacturer: CHIESI
    Approval date: October 14, 2011
    Strength(s): 500MG [RLD] [AB]
  • Manufacturer: CHIESI
    Approval date: July 25, 2019
    Strength(s): 1GM [RLD]
  • Manufacturer: CHIESI
    Approval date: May 19, 2020
    Strength(s): 1GM [RLD]

Has a generic version of Ferriprox been approved?

A generic version of Ferriprox has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ferriprox and have been approved by the FDA:

deferiprone tablet;oral

  • Manufacturer: HIKMA PHARMS
    Approval date: March 29, 2021
    Strength(s): 500MG [AB]
  • Manufacturer: TARO PHARM INDS LTD
    Approval date: February 8, 2019
    Strength(s): 500MG [AB]

Note: No generic formulation of the following product is available.

  • deferiprone - solution;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ferriprox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,780,055

    Patent expiration dates:

    • October 25, 2038
      ✓ 
      Patent use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
      ✓ 
      Drug product
  • Patent 10,940,115

    Patent expiration dates:

    • October 25, 2038
      ✓ 
      Patent use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
      ✓ 
      Drug product
  • Patent 10,940,116

    Patent expiration dates:

    • October 25, 2038
      ✓ 
      Drug product
  • Use for deferiprone
    Patent 7,049,328
    Issued: May 23, 2006
    Inventor(s): Spino; Michael & Piga; Antonio
    Assignee(s): Apotex Inc.

    A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat iron induced cardiac disease normally associated with iron overload.

    Patent expiration dates:

    • June 28, 2021
      ✓ 
      Patent use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
  • Liquid formulation for deferiprone with palatable taste
    Patent 8,703,156
    Issued: April 22, 2014
    Assignee(s): Apotex Technologies Inc.

    An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per liter of liquid composition, an effective amount of a thickening and suspension aid, (for example hydroxyethylcellulose), per liter of liquid composition, an effective amount of a humectant (such as glycerin) per liter of liquid composition, and an effective amount of at least one flavoring agent, wherein a final form of said taste-masked pharmaceutical has a substantially non-bitter and palatable taste.

    Patent expiration dates:

    • October 26, 2029
      ✓ 
      Patent use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • April 30, 2024 - TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.